# The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

> **NCT04068246** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sadat City University** · enrollment: 120 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04068246
- **Lead sponsor:** Sadat City University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-02-28
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068246, "The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04068246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*